This method demonstrates significant gains in accuracy and sustainability for solubility measurements, reducing CO2 emissions.
The pharmaceutical industry is responsible for 4.4% of global CO2 emissions. Assays used in drug discovery and development are major contributors to waste, including solubility measurements. These are either accurate but slow and energy-intensive (HPLC, centrifugation, filtration), contributing significantly to global CO2 emissions, or fast and economical but inaccurate (turbidity/nephelometry). Here, we exploit the sensitivity of high-throughput angle-resolved second harmonic scattering to detect nanoscale interfacial fluctuations in the solvent around the solute. Classical nucleation theory and nonlinear light scattering modeling show that, prior to aggregation, the solvent interfacial area changes drastically. This leads to changes in the standard deviation of the intensity at specific scattering angles, which can be used to obtain insights into the solubilizing mechanism. Exploiting the coherent nature of the emission, the detection limit for solubility/aggregation is reduced from ∼1 μM to ∼1 nM, achieving over a thousandfold sustainability gain, potentially permitting a reduction in the pharmaceutical industry's global CO2 emissions by ∼3.5%.
No takes yet. Share an insight, caveat, or question.
Tarun et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: